Allergic Disease Research:
  • The Doherty lab studies the involvement of group 2 innate lymphoid cells (ILC2s) in allergic diseases including: asthma, allergic rhinitis, chronic rhinosinusitis, aspirin exacerbated respiratory disease (AERD), and eosinophilic esophagitis (EoE).
Research Highlights:
  • July 2017, study entitled “Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease” was published in the Journal of Allergy and Clinical Immunology.  This article was highlighted in the journal’s Editor’s Choice feature.
  • August 2017, study entitled “Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation” was published in the Journal of Immunology.
  • July 2013, study entitled “Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production” was published in the Journal of Allergy and Clinical Immunology.
  • May 2011, study entitled “The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling” was published in Nature Medicine.
Funding for the Doherty lab has been provided by: The National Institute of Allergy and Infectious Disease (NIAID), the American Lung Association (ALA), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and UCSD CTRI.

i. UCSD: David Broide, M.B. Ch.B.
ii. UCSD Sinus Center: 
  • Sandra Christiansen, M.D.
  • Adam DeConde, M.D.
  • Bruce Zuraw, M.D.
  • Alex Kim, M.D.
iii. Scripps Clinic: Andrew White, M.D.
iv. The Scripps Research Institute: Peter Vanderklish, Ph.D.
v. The La Jolla Institute for Allergy and Immunology: Michael Croft, Ph.D.